TYROSINE KINASE INHIBITORS REGULATE SEROTONIN UPTAKE IN PLATELETS (VOL 280, PG R5, 1995)

被引：2

作者：

HELMESTE, DM ^{[1
]}

TANG, SW ^{[1
]}

机构：

[1] UNIV CALIF IRVINE,IRVINE MED CTR,DEPT PSYCHIAT,ORANGE,CA 92668

来源：

EUROPEAN JOURNAL OF PHARMACOLOGY | 1995年 / 286卷 / 01期

关键词：

GENISTEIN; ERBSTATIN ANALOG; CA2+;

D O I：

10.1016/0014-2999(95)00553-W

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Uptake of tritiated serotonin into human platelets was found to be rapidly inhibited by the tyrosine kinase inhibitors, genistein and methyl 2,5-dihydroxycinnamate. Binding studies indicated that uptake inhibition did not correlate with direct binding of these inhibitors to the transporter. Chelation of mobilizable intracellular Ca2+ did not inhibit the effects of genistein on uptake. These results suggest a more direct, non-Ca2+ mediated effect of tyrosine kinase inhibitors on uptake.

引用

页码：113 / 113

页数：1

共 50 条

[41] Clinical impact of dose reductions and interruptions of second generation tyrosine kinase inhibitors in patients with chronic myeloid leukaemia (vol 150, pg 303, 2010)
Santos, Fabio P. S.
BRITISH JOURNAL OF HAEMATOLOGY, 2011, 155 (03) : 409 - 409
[42] Design and Synthesis of Orally Bioavailable Benzimidazole Reverse Amides as Pan RAF Kinase Inhibitors (vol 5, pg 989, 2014)
Subramanian, Sharadha
Costales, Abran
Williams, Teresa E.
Levine, Barry
McBride, Christopher M.
Poon, Daniel
Amiri, Payman
Renhowe, Paul A.
Shafer, Cynthia M.
Stuart, Darrin
Verhagen, Joelle
Ramurthy, Savithri
ACS MEDICINAL CHEMISTRY LETTERS, 2014, 5 (12): : 1340 - 1340
[43] MET gene amplification or EGFR mutation activate MET in lung cancers untreated with EGFR tyrosine kinase inhibitors (vol 15, pg 1778, 2009)
Kubo, T.
Yamamoto, H.
Lockwood, W. W.
Valencia, I
Soh, J.
Peyton, M.
Jida, M.
Otani, H.
Fujii, T.
Ouchida, M.
Takigawa, N.
Kiura, K.
Shimizu, K.
Date, H.
Minna, J. D.
Varella-Garcia, M.
Lam, W. L.
Gazdar, A. F.
Toyooka, S.
INTERNATIONAL JOURNAL OF CANCER, 2015, 136 (02) : E1 - E1
[44] Prosnostic Significance of Prognostic Nutrition Index in Metastatic Renal Cell Carcinoma Patients Treated with Tyrosine Kinase Inhibitors (vol 10, pg 228, 2022)
Tacar, S. Y.
Yilmaz, M.
Gulturk, I
Tural, D.
NAMIK KEMAL MEDICAL JOURNAL, 2022, 10 (04): : 1 - 1
[45] Syk interacts with tyrosine-phosphorylated proteins in human platelets activated by collagen and cross-linking of the Fc gamma-IIA receptor (vol 311, pg 471, 1995)
Yanaga, F
Poole, A
Asselin, J
Blake, R
Schieven, G
Clark, EA
Law, CL
Watson, SP
BIOCHEMICAL JOURNAL, 1996, 313 : 1047 - 1047
[46] Prozac (fluoxetine, Lilly 110140), the first selective serotonin uptake inhibitor and an antidepressant drug twenty years since its first publication (vol 57, pg 411, 1995)
Carlsson, A
Wong, DT
LIFE SCIENCES, 1997, 61 (12) : 1203 - 1203
[47] Comparative evaluation of trimeric envelope glycoproteins derived from subtype C and B HIV-1 R5 isolates (vol 372, pg 273, 2008)
Srivastava, Indresh K.
Kan, Elaine
Sun, Yide
Sharma, Victoria A.
Cisto, Jimna
Burke, Brian
Lian, Ying
Hilt, Susan
Biron, Zohar
Hartog, Karin
Stamatatos, Leonidas
Diaz-Avalos, Ruben
Cheng, R. Holland
Ulmer, Jeffrey B.
Barnett, Susan W.
VIROLOGY, 2008, 381 (02) : 287 - 287
[48] HLA Polymorphisms Are Associated With Treatment-Free Remission Following Discontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia (vol 20, pg 142, 2021)
Ureshino, Hiroshi
Shindo, Takero
Tanaka, Hidenori
Saji, Hiroh
Kimura, Shinya
MOLECULAR CANCER THERAPEUTICS, 2022, 21 (05) : 855 - 855
[49] Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours (vol 120, pg 612, 2019)
Serrano, Cesar
Marino-Enriquez, Adrian
Tao, Derrick L.
Ketzer, Julia
Eilers, Grant
Zhu, Meijun
Yu, Channing
Mannan, Aristotle M.
Rubin, Brian P.
Demetri, George D.
Raut, Chandrajit P.
Presnell, Ajia
McKinley, Arin
Heinrich, Michael C.
Czaplinski, Jeffrey T.
Sicinska, Ewa
Bauer, Sebastian
George, Suzanne
Fletcher, Jonathan A.
BRITISH JOURNAL OF CANCER, 2019, 121 (03) : 281 - 281
[50] Immunotherapy and Tyrosine Kinase Inhibitors in metastatic Renal Cell Carcinoma in First-line Therapy - Which Strategy when? (vol 59, pg 1504, 2020)
Mickisch, G.
Peters, I.
Gruellich, C.
Mudra, T.
Doehn, C.
UROLOGE, 2021, 60 (03): : 381 - 382

← 1 2 3 4 5 →